-
Founded in:
2011-12-19 -
Country:
China -
Address:
No. 39, Pingtai 2nd Street, Benxi Economic and Technological Development Zone -
Tax NO.:
912105005873118435 -
Registered Funds:
50 million yuan -
Email:
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Cervi Cornu Panto Trichum |
|
0 | ||
| Ziziphi Apinoae Semen |
|
0 | ||
| CERVI CORNUS COLLA |
|
0 | ||
| SEMEN PLATYCLADI |
|
0 | ||
| Astragali Radix |
|
0 | ||
| ASIAN GINSENG |
|
0 | ||
| Angelica (wine) |
|
0 | ||
| Epimedium (processed) |
|
0 | ||
| Radix Aconiti Lateralis Preparata Rhizoma Cyperi extract |
|
0 | ||
| CISTANCHES HERBA |
|
0 | ||
| REHMANNIAE RADIX PRAEPARATA |
|
0 | ||
| SEMEN ALLII TUBEROSI |
|
0 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Loquat leaves |
|
0 | ||
| Mori Cortex |
|
0 | ||
| CYNANCHI STAUNTONII RHIZOMA ET RADIX |
|
0 | ||
| STEMONAE RADIX |
|
0 | ||
| Platycodonis Radix |
|
0 | ||
| DL-Menthol |
|
89-78-1 | 8 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Ozagrel sodium |
This product is a thromboxane synthetase inhibitor that can inhibit the production of TXA2, thus having the effects of anti-platelet aggregation and vasodilation. Animal experiments have shown that intravenous administration can reduce plasma TXB2 levels and the Keto-PGF12/TXB2 ratio, inhibit platelet aggregation caused by different inducers, and prevent cerebral infarction caused by the middle cerebral artery in rats.
More
This product is a thromboxane synthetase inhibitor that can inhibit the production of TXA2, thus having the effects of anti-platelet aggregation and vasodilation. Animal experiments have shown that intravenous administration can reduce plasma TXB2 levels and the Keto-PGF12/TXB2 ratio, inhibit platelet aggregation caused by different inducers, and prevent cerebral infarction caused by the middle cerebral artery in rats. |
189224-26-8 | 10 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Ozagrel sodium |
This product is a thromboxane synthetase inhibitor that can inhibit the production of TXA2, thus having the effects of anti-platelet aggregation and vasodilation. Animal experiments have shown that intravenous administration can reduce plasma TXB2 levels and the Keto-PGF12/TXB2 ratio, inhibit platelet aggregation caused by different inducers, and prevent cerebral infarction caused by the middle cerebral artery in rats.
More
This product is a thromboxane synthetase inhibitor that can inhibit the production of TXA2, thus having the effects of anti-platelet aggregation and vasodilation. Animal experiments have shown that intravenous administration can reduce plasma TXB2 levels and the Keto-PGF12/TXB2 ratio, inhibit platelet aggregation caused by different inducers, and prevent cerebral infarction caused by the middle cerebral artery in rats. |
189224-26-8 | 10 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Ozagrel sodium |
This product is a thromboxane synthetase inhibitor that can inhibit the production of TXA2, thus having the effects of anti-platelet aggregation and vasodilation. Animal experiments have shown that intravenous administration can reduce plasma TXB2 levels and the Keto-PGF12/TXB2 ratio, inhibit platelet aggregation caused by different inducers, and prevent cerebral infarction caused by the middle cerebral artery in rats.
More
This product is a thromboxane synthetase inhibitor that can inhibit the production of TXA2, thus having the effects of anti-platelet aggregation and vasodilation. Animal experiments have shown that intravenous administration can reduce plasma TXB2 levels and the Keto-PGF12/TXB2 ratio, inhibit platelet aggregation caused by different inducers, and prevent cerebral infarction caused by the middle cerebral artery in rats. |
189224-26-8 | 10 |